Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: An analysis of animal studies, observational studies, and clinical trials

Review of Diabetic Studies

Volumn 10, Issue 2-3, 2013, Pages 110-120

  Hung, Chi Chih ^a   Tsai, Jer Chia ^a,b   Kuo, Hung Tien ^a,b   Chang, Jer Ming ^a,b,c   Hwang, Shang Jyh ^a,b   Chen, Hung Chun ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Albuminuria; Diabetic kidney disease; Dyslipoproteinemia; Lipid; Lipoprotein; Renal disease; Triglyceride; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E2; ATORVASTATIN; CREATININE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN A; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALBUMINURIA; APOPTOSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG MEGADOSE; DYSLIPOPROTEINEMIA; FIBROSIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATORY CELL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIPID METABOLISM; LOW DRUG DOSE; MESANGIUM CELL; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUBULOINTERSTITIAL FIBROSIS;

ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891785298     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2013.10.110     Document Type: Review

References (110)

1. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med 2006. 166(17):1884-1891.
2. Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996. 45(10):1267-1272.
3. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005. 16(12):3748-3754.
4. Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003. 26(5):1402-1407.
5. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997. 314(7083):783-788.
6. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995. 47(3):907-910.
7. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003. 14(8):2084-2091.
8. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004. 15(3):538-548.
9. Newman JW, Kaysen GA, Hammock BD, Shearer GC. Proteinuria increases oxylipid concentrations in VLDL and HDL but not LDL particles in the rat. J Lipid Res 2007. 48(8):1792-1800.
10. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011. 377(9784):2181-2192.
11. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001. 414(6865):782-787.
12. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, Ukpds G. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003. 63(1):225-232.
13. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, Group US. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006. 55(6):1832-1839.
14. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW, American Diabetes A. Nephropathy in diabetes. Diabetes Care 2004. 27 Suppl 1:S79-S83.
15. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000. 160(8):1093-1100.
16. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004. 27(1):195-200.
17. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003. 289(24):3273-3277.
18. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007. 49(2 Suppl 2):S12-S154.
19. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996. 39(12):1569-1576.
20. Osterby R, Parving HH, Hommel E, Jorgensen HE, Lokkegaard H. Glomerular structure and function in diabetic nephropathy. Early to advanced stages. Diabetes 1990. 39(9):1057-1063.
21. Mauer SM, Steffes MW, Brown DM. The kidney in diabetes. Am J Med 1981. 70(3):603-612.
22. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000. 26 Suppl 4:8-14.
23. Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol 1993. 3(8):1458-1466.
24. Olsen S, Mogensen CE. How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia 1996. 39(12):1638-1645.
25. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005. 28(1):164-176.
26. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982. 2(8311):1309-1311.
27. Fredrickson DS, Lees RS. A System for Phenotyping Hyperlipoproteinemia. Circulation 1965. 31:321-327.
28. Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol 2008. 28(5):723-731.
29. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008. 28(6):958-973.
30. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004. 140(1):9-17.
31. Ginsberg HN. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006. 91(2):383-392.
32. Walzem RL, Watkins S, Frankel EN, Hansen RJ, German JB. Older plasma lipoproteins are more susceptible to oxidation: a linking mechanism for the lipid and oxidation theories of atherosclerotic cardiovascular disease. Proc Natl Acad Sci U S A 1995. 92(16):7460-7464.
33. Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 2003(84):S121-124.
34. Farbakhsh K, Kasiske BL. Dyslipidemias in patients who have chronic kidney disease. Med Clin North Am 2005. 89(3):689-699.
35. Ruan XZ, Moorhead JF, Varghese Z. Lipid redistribution in renal dysfunction. Kidney Int 2008. 74(4):407-409.
36. Ruan XZ, Varghese Z, Moorhead JF. An update on thelipid nephrotoxicity hypothesis. Nat Rev Nephrol 2009. 5(12):713-721.
37. Kimmelstiel P, Wilson C. Intercapillary Lesions in the Glomeruli of the Kidney. Am J Pathol 1936. 12(1):83-98 87.
38. Grond J, van Goor H, Erkelens DW, Elema JD. Glomerular sclerotic lesions in the rat. Histochemical analysis of their macromolecular and cellular composition. Virchows Arch B Cell Pathol Incl Mol Pathol 1986. 51(6):521-534.
39. Lee HS, Lee JS, Koh HI, Ko KW. Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991. 36(2):67-75.
40. Shioi A, Fujimoto T. Disorganization process in the development of diabetic nodular glomerulosclerosis. Tohoku J Exp Med 1989. 159(4):257-275.
41. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 1988. 33(5):917-924.
42. Chiang YY, Takebayashi S, Oberley TD. In vitro analysis of extracellular matrix production by porcine glomerular mesangial and vascular smooth muscle cells. Am J Pathol 1991. 138(6):1349-1358.
43. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 1985. 82(17):5963-5967.
44. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990. 37(3):880-891.
45. Hattori M, Nikolic-Paterson DJ, Miyazaki K, Isbel NM, Lan HY, Atkins RC, Kawaguchi H, Ito K. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int Suppl 1999. 71:S47-50.
46. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 1995. 26(1):152-161.
47. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001. 11(3-4):93-102.
48. Lee HS, Kim YS. Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 1998. 54(3):848-856.
49. Heeringa P, Tervaert JW. Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens 2002. 11(3):287-293.
50. Chen HC, Guh JY, Shin SJ, Lai YH. Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis 2002. 160(1):141-146.
51. Nosadini R, Tonolo G. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis 2011. 21(2):79-85.
52. Grone EF, Walli AK, Grone HJ, Miller B, Seidel D. The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 1994. 107(1):1-13.
53. Rayner HC, Ross-Gilbertson VL, Walls J. The role of lipids in the pathogenesis of glomerulosclerosis in the rat following subtotal nephrectomy. Eur J Clin Invest 1990. 20(1):97-104.
54. Kaplan R, Aynedjian HS, Schlondorff D, Bank N. Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol. J Clin Invest 1990. 86(5):1707-1714.
55. Grone HJ, Walli A, Grone E, Niedmann P, Thiery J, Seidel D, Helmchen U. Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat. Lab Invest 1989. 60(3):433-446.
56. Keane WF. Lipids and progressive renal failure. Wien Klin Wochenschr 1996. 108(14):420-424.
57. Albright AL, Johnson PR, Greene S, Stern JS. Use of glycated hemoglobin to assess Glycemic control in Wistar diabetic fatty rats and Zucker fatty rats. Obes Res 1994. 2(6):535-539.
58. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988. 33(3):667-672.
59. Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992. 19(1 Suppl):I110-I115.
60. Dominguez JH, Tang N, Xu W, Evan AP, Siakotos AN, Agarwal R, Walsh J, Deeg M, Pratt JH, March KL, et al. Studies of renal injury III: lipid-induced nephropathy in type II diabetes. Kidney Int 2000. 57(1):92-104.
61. Chapman MJ. Comparative analysis of mammalian plasma lipoproteins. Methods Enzymol 1986. 128:70-143.
62. Gades MD, Stern JS, van Goor H, Nguyen D, Johnson PR, Kaysen GA. Estrogen accelerates the development of renal disease in female obese Zucker rats. Kidney Int 1998. 53(1):130-135.
63. Shohat J, Erman A, Zandbank J, Harell D, Boner G. Renal effects of moderate hypercholesterolaemia in uninephrectomized rats. Scand J Clin Lab Invest 1996. 56(4):339-343.
64. Scheuer H, Gwinner W, Hohbach J, Grone EF, Brandes RP, Malle E, Olbricht CJ, Walli AK, Grone HJ. Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol 2000. 278(1):F63-74.
65. Ellis D, Orchard TJ, Lombardozzi S, Yunis EJ, McCauley J, Agostini R, Diamond JR. Atypical hyperlipidemia and nephropathy associated with apolipoprotein E homozygosity. J Am Soc Nephrol 1995. 6(4):1170-1177.
66. Suzaki K, Kobori S, Ueno S, Uehara M, Kayashima T, Takeda H, Fukuda S, Takahashi K, Nakamura N, Uzawa H, et al. Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 1990. 80(3):181-189.
67. Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, Koga T, Arakawa K, Oikawa S, Saito T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int 1999. 56(2):421-427.
68. Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trends Cardiovasc Med 2002. 12(2):67-70.
69. Liberopoulos E, Siamopoulos K, Elisaf M. Apolipoprotein E and renal disease. Am J Kidney Dis 2004. 43(2):223-233.
70. Utermann G, Kindermann I, Kaffarnik H, Steinmetz A. Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet 1984. 65(3):232-236.
71. Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS. APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes 2000. 49(12):2190-2195.
72. Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, Yoneda M, Matsuki M, Takigami S, Kaku K. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002. 40(2):243-251.
73. Hsu CC, Kao WH, Coresh J, Pankow JS, Marsh-Manzi J, Boerwinkle E, Bray MS. Apolipoprotein E and progression of chronic kidney disease. JAMA 2005. 293(23):2892-2899.
74. Schainuck LI, Striker GE, Cutler RE, Benditt EP. Structural-functional correlations in renal disease. II. The correlations. Hum Pathol 1970. 1(4):631-641.
75. Ueno M, Kawashima S, Nishi S, Shimada H, Karasawa R, Suzuki Y, Maruyama Y, Arakawa M. Tubulointerstitial lesions in non-insulin dependent diabetes mellitus. Kidney Int Suppl 1997. 63:S191-194.
76. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984. 74(4):1143-1155.
77. Eddy AA. Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades. Kidney Int 1998. 53(5):1182-1189.
78. Grone HJ, Hohbach J, Grone EF. Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl 1996. 54:S18-22.
79. Lavaud S, Poirier B, Mandet C, Belair MF, Irinopoulou T, Heudes D, Bazin R, Bariety J, Myara I, Chevalier J. Inflammation is probably not a prerequisite for renal interstitial fibrosis in normoglycemic obese rats. Am J Physiol Renal Physiol 2001. 280(4):F683-694.
80. Magil AB. Tubulointerstitial lesions in young Zucker rats. Am J Kidney Dis 1995. 25(3):478-485.
81. Kriz W, Hosser H, Hahnel B, Gretz N, Provoost AP. From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: a histopathological study in rat models and human glomerulopathies. Nephrol Dial Transplant 1998. 13(11):2781-2798.
82. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999. 56(5):1627-1637.
83. Gorriz JL, Martinez-Castelao A. Proteinuria: detection and role in native renal disease progression. Transplant Rev (Orlando) 2012. 26(1):3-13.
84. Okamura DM, Lopez-Guisa JM, Koelsch K, Collins S, Eddy AA. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol 2007. 293(2):F575-F585.
85. Fox CS, Muntner P. Trends in diabetes, high cholesterol, and hypertension in chronic kidney disease among U.S. adults: 1988-1994 to 1999-2004. Diabetes Care 2008. 31(7):1337-1342.
86. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, Panarelli W, De Santo NG. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med 1998. 158(17):1933-1939.
87. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000. 58(1):293-301.
88. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009. 169(4):342-350.
89. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997. 51(6):1908-1919.
90. Greene T, Bourgoignie JJ, Habwe V, Kusek JW, Snetselaar LG, Soucie JM, Yamamoto ME. Baseline characteristics in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 1993. 4(5):1221-1236.
91. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000. 15(1):34-42.
92. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Weiss L, Alaupovic P. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998. 9(8):1482-1488.
93. Boes E, Fliser D, Ritz E, Konig P, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Riegler P, Kronenberg F. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2006. 17(2):528-536.
94. Toth T, Takebayashi S. Factors contributing to the outcome in 100 adult patients with idiopathic membranous glomerulonephritis. Int Urol Nephrol 1994. 26(1):93-106.
95. Chen SC, Hung CC, Kuo MC, Lee JJ, Chiu YW, Chang JM, Hwang SJ, Chen HC. Association of dyslipidemia with renal outcomes in chronic kidney disease. Plos One 2013. 8(2):e55643.
96. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006. 55(6):1832-1839.
97. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001. 59(1):260-269.
98. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006. 17(7):2006-2016.
99. Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, Rutks I, Wilt TJ. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis 2012. 60(5):747-769.
100. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008. 336(7645):645-651.
101. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005. 112(2):171-178.
102. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003. 14(6):1605-1613.
103. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003. 361(9374):2005-2016.
104. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004. 57(7):728-734.
105. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH, Investigators C. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009. 54(5):810-819.
106. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003. 361(9374):2005-2016.
107. Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, Liyanage T, Keech A, Cass A, Perkovic V. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2012. 60(20):2061-2071.
108. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis 2004. 44(5):832-839.
109. Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010. 362(17):1563-1574.
110. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008. 358(24):2545-2559.